Updated Results on Long Term Overall Survival (OS) of the French Randomized Phase II Trial TORAVA in Metastatic Renal Cell Carcinoma (mRCC) Patients

摘要

The randomized, phase II TORAVA (Combination of Temsirolimus and Bevaci-zumab in Patient With Metastatic Renal Cell Carcinoma) trial investigated the safety and efficacy of combining temsirolimus and bevacizumab in previously untreated patients witli metastatic RCC. The study showed that the combination of temsirolimus plus bevacizumab failed to increase PFS over standard treatment. Moreover, adding temsirolimus to bevacizumab caused unexpectedly high toxicity. Extending these initial results, Jacques-Olivier Bay, MD, PhD, presented long-term results on OS and information on second-line therapy after failure from the TORAVA trial.